Cover Image
市場調查報告書

生物醫藥品用幹細胞株培養市場 (工程,培養方法,各地區) - 全球產業分析,規模,構成比,成長率,趨勢及預測:2015-2022年

Biotherapeutics Cell Line Development Market (by Process, CLD Option and by Geography): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2022

出版商 Transparency Market Research 商品編碼 350554
出版日期 內容資訊 英文 104 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
生物醫藥品用幹細胞株培養市場 (工程,培養方法,各地區) - 全球產業分析,規模,構成比,成長率,趨勢及預測:2015-2022年 Biotherapeutics Cell Line Development Market (by Process, CLD Option and by Geography): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2022
出版日期: 2015年12月18日 內容資訊: 英文 104 Pages
簡介

美國食品藥物管理局 (FDA) 對基因改造蛋白質治療法的認證量逐年增加,生物醫藥品用幹細胞株培養的需求也在日益擴大。2006-2011年這段期間有15件,2014年有11件重組蛋白治療法通過認証,歐洲之外全球各地的批准數量加起來,則有47件單株抗體產品通過核准,其6成多為哺乳類細胞培養生產。疾病的增加,高齡人口的擴大,都是推動生物醫藥品上幹細胞株培養的主因之一。再加上單株抗體的全球性增加,以及各國政府強化研究支援,預測市場在今後數年將會加速成長。

本報告以生物醫藥品用幹細胞株培養技術的全球市場為焦點,依工程,培養方法,地區別預測2015-2022年這段期間的交易規模轉變,同時更彙整產業結構,供需趨勢,推動·阻礙因素,機會,競爭環境等分析資訊和主要加入企業簡介。

第1章 序

  • 報告說明
  • 調查方法
  • 市場區隔
  • 前提

第2章 摘要整理

  • 市場簡述:生物醫藥品用幹細胞株培養的全球市場
  • 比較分析:生物醫藥品用幹細胞株培養的全球市場 - 各地區:2014年 vs. 2022年

第3章 生物醫藥品用幹細胞株培養市場 - 概要

  • 簡介
  • 市場動態
    • 推動要素
    • 阻礙因素
    • 機會
  • 生物醫藥品用幹細胞株培養的現場:定性分析:2014年
  • 市場向心力分析 - 生物醫藥品用幹細胞株培養市場 - 各地區:2014年
  • 競爭環境 - 螢光活化細胞分選部門 (FACS) 市場
  • 木質磺酸鹽:各企業市場佔有率分析:2014年
    • 以金額為準的市場佔有率 - 主要企業:2014年 (金額構成比)

第4章 生物醫藥品用幹細胞株培養的全球市場收益 - 各工程:2014-2022年 (單位:100萬美元)

  • 簡介
  • 運入 (轉染) 部門與分選 (selection)
  • 單細胞基因複製
    • 手動限制基因複製 (CloneSelect等的單細胞成像器)
    • FACS
    • ClonePix

第5章 生物醫藥品用幹細胞株培養的全球市場收益 - 培養方法 (CLD) 各:2014-2022年 (單位:100萬美元)

  • 簡介
  • 內製
  • 外部委託
  • DIY
  • 混合

第6章 生物醫藥品用幹細胞株培養的全球市場收益 - 各地區:2014-2022年 (單位:100萬美元)

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 中南美
  • 中東·非洲

第7章 建議

  • 過去及今後趨勢
  • 成功的障礙

第8章 企業簡介 (企業概要,財務概況,產品系列,產業策略,最新發展)

  • Becton, Dickinson and Company
  • Beckman Coulter, Inc. (Danaher Corporation)
  • Boehringer Ingelheim Pharma GmbH & Co KG.
  • Catalent, Inc.
  • CMC Biologics
  • Lonza Group Ltd.
  • Partec (Sysmex Corporation)
  • ProBioGen AG
  • SAFC (Sigma-Aldrich Corporation)
  • Selexis SA
  • Sony Biotechnology Inc. (SONY株式會社)
  • Thermo Fisher Scientific, Inc.
  • 其他
目錄

With the increasing number of recombinant protein therapeutics gaining approval by the U.S. Food and Drug Administration (FDA) annually, there is an increase in the demand of cell lines for production of these biotherapeutics. From 2006 to 2011 an average of 15 novel recombinant protein therapeutics and in 2014, 11 novel recombinant protein therapeutics have been approved by US FDA. About forty-seven monoclonal antibody products have been approved in the U.S., Europe and other global markets, of which over 60% were produced in mammalian cell culture. Moreover, the rise in the geriatric population coupled with prevalence of diseases is one of the major factors driving the demand for cell line development for biotherapeutics. The increasing demand for monoclonal antibodies across the globe boosts the market growth. In addition, the increasing number of initiatives taken by the government of various countries by funding the life science research and development is expected to propel this market in coming years.

The global biotherapeutics cell line development market is segmented by process, by cell line development option and by geography. The market by process segment has been sub-segmented as transfection and single cell cloning. The single cell cloning market is further sub-segmented by method into manual limited dilution cloning, FACS, ClonePix and Others. The market by CLD option is segmented as In-house, outsource, hybrid and do-it-yourself. The ClonePix accounted for the largest market share of 37.4% in 2014. Geographically, the market has been studied and estimated for five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

The market overview section of the report demonstrates major market dynamics such as drivers, restraints, and opportunities that influence the current and future status of the industry. The market overview section includes market attractiveness analysis, by geography, to provide a thorough analysis of the overall competitive scenario in the global biotherapeutics cell line development market. The market overview section of the report also includes the qualitative and quantitative analysis of the competitive landscape.

Market share analysis for FACS market is also provided in the market overview section of the report for 2014 in terms of value (%). The report also provides important recommendations for market players and new entrants. These recommendations would enable existing market players to expand their market shares and help new companies to establish their presence in the biotherapeutics cell line development market across the world. The report concludes with the company profiles section, which includes key information about major players in the market such as financial overview, business strategies, and recent developments. Major players in this market are Becton Dickinson & Company (U.S.), Beckman Coulter (U.S.), Boehringer Ingelheim Group (Germany), Catalent Inc. (U.S.), CMC Biologics A/S (Denmark), Lonza Group Ltd. (Switzerland), EMD Millipore (U.S.), Partec (Sysmex Corporation) (Japan), ProBioGen AG (Germany), Selexis SA (Germany), Sigma-Aldrich Co. LLC. (U.S.), Sony Biotechnology Inc. (U.S.), and Thermo Fisher Scientific Inc. (U.S.).

The global biotherapeutics cell line development market has been segmented as follows:

Global Biotherapeutics Cell Line Development Market, by Process

  • Transfection & Selection
  • Single Cell Cloning
    • Manual limited dilution cloning
    • FACS
    • ClonePix
    • Others

Global Biotherapeutics Cell Line Development Market, by CLD Option

  • In-house
  • Outsource
  • Hybrid
  • Do-It-Yourself (DIY)

Global Medical Cameras and Microscopes Market, by Geography

  • North America
  • Europe
  • Asia Pacific (APAC)
  • Latin America (LATAM)
  • Middle East & Africa

Table of Contents

Chapter 1 Introduction

  • 1.1 Report Description
  • 1.2 Research Methodology
  • 1.3 Market Segmentation
  • 1.4 Assumptions

Chapter 2 Executive Summary

  • 2.1 Market Snapshot: Global Biotherapeutics Cell Line Development Market
  • 2.2 Comparative Analysis: Global Biotherapeutics Cell Line Development Market, by Geography, 2014 & 2022

Chapter 3 Biotherapeutics Cell Line Development Market Overview

  • 3.1 Introduction
  • 3.2 Market Dynamics
    • 3.2.1 Drivers
    • 3.2.2 Restraints
    • 3.2.3 Opportunities
  • 3.3 Biotherapeutics Cell Line Development Sites: Qualitative Analysis, 2014
  • 3.4 Market Attractiveness Analysis: Biotherapeutics Cell Line Development Market, by Geography, 2014
  • 3.5 Competitive Landscape: FACS Market
    • 3.5.1 Market Share by Revenue, by Key Players, 2014 (Value %)

Chapter 4 Global Biotherapeutics Cell Line Development Market Revenue, by Process, 2014 - 2022 (USD Million)

  • 4.1 Introduction
  • 4.2 Transfection & Selection
  • 4.3 Single Cell Cloning
    • 4.3.1 Manual Limited Dilution Cloning (e.g. Single Cell Imagers such as CloneSelect, etc.)
    • 4.3.2 FACS
    • 4.3.3 ClonePix

Chapter 5 Global Biotherapeutics Cell Line Development Market Revenue, by CLD Option, 2014 - 2022 (USD Million)

  • 5.1 Introduction
  • 5.2 In-house
  • 5.3 Outsource
  • 5.4 Do-it-yourself (DIY)
  • 5.5 Hybrid

Chapter 6 Global Biotherapeutics Cell Line Development Market Revenue, by Geography, 2014 - 2022 (USD Million)

  • 6.1 Introduction
  • 6.2 North America
  • 6.3 Europe
  • 6.4 Asia Pacific
  • 6.5 Latin America
  • 6.6 Middle East & Africa (MEA)

Chapter 7 Recommendations

  • 7.1 Past and Future Trends
  • 7.2 Barriers to success

Chapter 8 Company Profiles

  • 8.1 Becton, Dickinson and Company
    • 8.1.1 Company Overview
    • 8.1.2 Financial Overview
    • 8.1.3 Product Portfolio
    • 8.1.4 Business Strategies
    • 8.1.5 Recent Developments
  • 8.2 Beckman Coulter, Inc. (Danaher Corporation)
  • 8.3 Boehringer Ingelheim Pharma GmbH & Co KG.
  • 8.4 Catalent, Inc.
  • 8.5 CMC Biologics
  • 8.6 Lonza Group Ltd.
  • 8.7 Partec (Sysmex Corporation)
  • 8.8 ProBioGen AG
  • 8.9 SAFC (Sigma-Aldrich Corporation)
  • 8.10 Selexis SA
  • 8.11 Sony Biotechnology Inc. (Sony Corporation)
  • 8.12 Thermo Fisher Scientific, Inc.
  • 8.13 Others
Back to Top